Study supports single-dose COVID-19 vaccine strategy for pre

Study supports single-dose COVID-19 vaccine strategy for previously infected individuals


Study supports single-dose COVID-19 vaccine strategy for previously infected individuals
Researchers in the Netherlands have provided evidence that a single dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine is sufficient to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people who have already been infected with the virus.
The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose sparing strategies, particularly single vaccine dosing of individuals with prior SARS-CoV-2 infection,” says the team from the University of Amsterdam, the Public Health Service of Amsterdam and members of the RECoVERED Study Group.

Related Keywords

Netherlands , Amsterdam , Noord Holland , Sally Robertson , Pfizer , University Of Amsterdam , Study Group , Public Health Service Of Amsterdam , Public Health Service , Coronavirus Disease Covid 19 , Pandemic , Ars Cov 2 , Vaccine , Antibodies , Ntibody , Coronavirus , Healthcare , Protein , Public Health , Espiratory , Cars , Evere Acute Respiratory , Evere Acute Respiratory Syndrome , Spike Protein , Yndrome , Virus , நெதர்லாந்து , ஆம்ஸ்டர்டாம் , நூற்த் ஹாலண்ட் , சாலி ராபர்ட்சன் , ஃபைசர் , பல்கலைக்கழகம் ஆஃப் ஆம்ஸ்டர்டாம் , படிப்பு குழு , பொது ஆரோக்கியம் சேவை ஆஃப் ஆம்ஸ்டர்டாம் , பொது ஆரோக்கியம் சேவை , அரசு ,

© 2025 Vimarsana